Angina Research Today is a free monthly online journal that collates and summarizes the latest research about Angina, including details on symptoms, treatment, causes, prevention, surgery.

Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization.

Gluckman TJ, Segal JB, Fredde NL, Saland KE, Jani JT, Walenga JM, Prechel MM, Citro KM, Zidar DA, Fox E, Schulman SP, Kickler TS, Rade JJ

Department of Medicine Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA.

The incidence of antiplatelet factor-4/heparin antibody formation in patients who receive contemporary doses of unfractionated heparin in the setting of percutaneous coronary revascularization is unknown. Also unknown is the ability of these antibodies to activate platelets or adversely affect clinical outcome in the absence of clinically recognized heparin-induced thrombocytopenia. To address these questions, we serially measured antiplatelet factor-4/heparin antibody levels and performed serotonin release assays in patients who underwent percutaneous coronary intervention. Correlations were then made across antibody induction, heparin exposure, and clinical outcome at 6 months.

Published 10 March 2005 in Am J Cardiol, 95(6): 744-7.
Full-text of this article is available online (may require subscription).

© 2004-2008 Angina Research Today. All Rights Reserved.